
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Denileukin Diftitox
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : AmerisourceBergen
Deal Size : Undisclosed
Deal Type : Agreement
Citius Expands Distribution Network for LYMPHIR with Cencora
Details : Under the agreement, Cencora will execute the distribution process of Lymphir (denileukin diftitox). It is being indicated for the treatemnt of Stage I-III cutaneous T-cell lymphoma.
Product Name : Lymphir
Product Type : Protein
Upfront Cash : Undisclosed
July 15, 2025
Lead Product(s) : Denileukin Diftitox
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : AmerisourceBergen
Deal Size : Undisclosed
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Denileukin Diftitox
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : TenX Keane Acquisition
Deal Size : Undisclosed
Deal Type : Merger
Citius Completes Merger with TenX Keane to Form Citius Oncology, Inc.
Details : Lymphir (denileukin diftitox) is a specially engineered IL-2- diphtheria toxin fusion protein made using recombinant DNA technology for the treatment of cutaneous T-cell lymphoma.
Product Name : Lymphir
Product Type : Protein
Upfront Cash : Undisclosed
August 12, 2024
Lead Product(s) : Denileukin Diftitox
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : TenX Keane Acquisition
Deal Size : Undisclosed
Deal Type : Merger
